Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Subscribe To Our Newsletter & Stay Updated
